Brought to you by 
Five Prime partners again with Glaxo, this time in respiratory diseases
16 Apr 2021
Executive Summary
Five Prime Therapeutics Inc. (large-molecule candidates for cancer, respiratory, and autoimmune disorders) has granted GlaxoSmithKline PLC exclusive rights to its drug discovery tools--including the biotech’s library of functional human secreted proteins and transmembrane receptor proteins--to generate up to six respiratory disease programs.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com